Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGI 001 (s-pindolol) in functional dyspepsia
2004-002762-38Phase 2Completed
- Sponsor
- AGI Therapeutics plc
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in functional dyspepsia (FD) comparing AGI 001 (s-pindolol) with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Feb 2005; status: completed.
02
Drugs
espindolol
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on 2004-002762-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002762-38.